GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » PE Ratio without NRI

Broncus Holding (HKSE:02216) PE Ratio without NRI : At Loss (As of Apr. 07, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2025-04-07), Broncus Holding's share price is HK$0.83. Broncus Holding's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.38. Therefore, Broncus Holding's PE Ratio without NRI for today is At Loss.

Broncus Holding's EPS without NRI for the six months ended in Jun. 2024 was HK$-0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.38.

As of today (2025-04-07), Broncus Holding's share price is HK$0.83. Broncus Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.39. Therefore, Broncus Holding's PE Ratio (TTM) for today is At Loss.

Broncus Holding's EPS (Diluted) for the six months ended in Jun. 2024 was HK$-0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.39.

Broncus Holding's EPS (Basic) for the six months ended in Jun. 2024 was HK$-0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.39.


Broncus Holding PE Ratio without NRI Historical Data

The historical data trend for Broncus Holding's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding PE Ratio without NRI Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio without NRI
N/A N/A At Loss At Loss At Loss

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Broncus Holding's PE Ratio without NRI

For the Medical Devices subindustry, Broncus Holding's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Broncus Holding's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Broncus Holding's PE Ratio without NRI falls into.


;
;

Broncus Holding PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Broncus Holding's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=0.83/-0.383
=-2.17(At Loss)

Broncus Holding's Share Price of today is HK$0.83.
For company reported semi-annually, Broncus Holding's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.38.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Broncus Holding  (HKSE:02216) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Broncus Holding PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Broncus Holding's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Broncus Holding Business Description

Traded in Other Exchanges
N/A
Address
No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Executives
Xu Hong 2101 Beneficial owner
Zi Zhenjun
Xin Nuo Tong Investment Limited 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qm12 Limited 2101 Beneficial owner
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Computershare Hong Kong Trustees Limited 2301 Trustee
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited 2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines